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Antibacterial proteins are components of the innate
immune system found in many organisms and produced
by a variety of cell types. Human blood platelets contain
a number of antibacterial proteins in their a-granules
that are released upon thrombin activation. The present
study was designed to purify these proteins obtained
from human platelets and to characterize them chemi-
cally and biologically. Two antibacterial proteins were
purified from platelet granules in a two-step protocol
using cation exchange chromatography and continuous
acid urea polyacrylamide gel electrophoresis and were
designated thrombocidin (TC)-1 and TC-2. Characteriza-
tion of these proteins using mass spectrometry and N-
terminal sequencing revealed that TC-1 and TC-2 are
variants of the CXC chemokines neutrophil-activating
peptide-2 and connective tissue-activating peptide-III,
respectively. TC-1 and TC-2 differ from these chemo-
kines by a C-terminal truncation of 2 amino acids. Both
TCs, but not neutrophil-activating peptide-2 and con-
nective tissue-activating peptide-III, were bactericidal
for Bacillus subtilis, Escherichia coli, Staphylococcus
aureus, and Lactococcus lactis and fungicidal for Cryp-
tococcus neoformans. Killing of B. subtilis by either TC
appeared to be very rapid. Because TCs were unable to
dissipate the membrane potential of L. lactis, the mech-
anism of TC-mediated killing most probably does not
involve pore formation.
During the last decade, antibacterial proteins have been
recognized as effector molecules in the innate immune system
of widely divergent animal species (1–5). The cationic nature of
the vast majority of these proteins is thought to be crucial to
target and disrupt microbial membranes (6). Based on their
primary structure, antibacterial proteins are classified in four
groups. The largest group found thus far is formed by the
b-stranded proteins, containing 4–6 conserved cysteines inter-
linked by disulfide bridges. Defensins are probably the best
studied members of this group. Other classes consist of am-
phipathic a-helical proteins, proline-rich coiled proteins, and
looped or cyclic proteins (6, 7).
The antibacterial proteins found in man are distributed over
a variety of tissues and cell types. They have been found in
leukocytes, most abundantly in polymorphonucleated neutro-
phils, where they are thought to be involved in the killing of
engulfed bacteria (8). More recently, cationic antibacterial pep-
tides have also been found in various epithelial tissues (9).
Enteric defensins are produced and secreted by human (10, 11)
and mouse (12, 13) Paneth cells. b-Defensins, first isolated
from bovine neutrophils (14) and epithelial tissue of tongue and
trachea (15–17), have recently been identified in human airway
(18, 19) and urogenital epithelial tissue (20), as well as in
plasma (21) and skin epithelial cells (22). Expression of some of
the epithelial proteins was found to be elevated after injury or
contact with lipopolysaccharide or bacteria (22–26), which in-
dicates their functionality in nonspecific host defense.
In addition to the cell types mentioned above, human and
rabbit blood platelets are known to store antibacterial proteins
(27–33). These antibacterial proteins are released from platelet
a-granules in vitro after activation with thrombin (27) and
were designated thrombocidins (34). In vivo, direct contact of
platelets with bacteria causes aggregation and activation of
platelets (35). The subsequently released antibacterial proteins
most likely are involved in the elimination of adherent bacteria
(36). Dankert et al. (27, 36) showed that antibacterial proteins
released from thrombin-activated platelets were involved in
the clearance of viridans streptococci from cardiac vegetations
in the rabbit experimental infective endocarditis (IE)1 model.
Viridans streptococci with low susceptibility to these proteins
persisted in vegetations, whereas highly susceptible bacteria
were rapidly eliminated (36). Similarly, strains of Staphylococcus
aureus and Candida albicans insusceptible to rabbit platelet
microbicidal proteins (PMPs) caused more severe experimental
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thrombocytopenic rabbits (39) or rabbits with antibodies neu-
tralizing their platelet bactericidal proteins (40) were more
susceptible to streptococcal IE than control rabbits. The pres-
ent study was undertaken to gain insight into the structure,
activity, and mechanism of action of antimicrobial proteins
present in human platelets.
EXPERIMENTAL PROCEDURES
Isolation of Human Blood Platelets—Citrated human blood from
healthy subjects was obtained from the Central Laboratory for Blood
Transfusion (Amsterdam, The Netherlands). Platelets were concen-
trated by the buffy coat method (41) and isolated using a protocol
adapted from Fukami (42) and Kaplan et al. (43). Buffy coats were
pooled in transfer bags (Netherlands Production Laboratory for Blood
Transfusion Equipment and Infusion Solutions, Emmer-Compascuum,
The Netherlands; 8 buffy coats/bag, approximately 550 ml), to which
200 ml of phosphate-buffered saline 1 0.38% trisodium citrate (w/v)
was added. The bags were blown tight with air and centrifuged for 5
min at 600 3 g at 20 °C. The upper three-quarters of the volume of each
bag, containing platelets, were transferred into new bags. To this plate-
let concentrate, one-ninth volume of citrate solution (75 mM trisodium
citrate, 38 mM citric acid) was added. The bags were blown tight again
and were centrifuged at 1750 3 g at 20 °C for 10 min. The supernatants
were removed, and platelets were resuspended in Tris-citrate (63 mM
Tris-HCl, 95 mM NaCl, 5 mM KCl, 12 mM citric acid, pH 6.5) by gentle
massage. The platelet suspensions were collected in a siliconized flask.
The bags were washed once with Tris-citrate, and this washing was
added to the platelet suspension. Processing of 48 buffy coats routinely
yielded approximately 75 ml of highly concentrated platelet suspension
containing less than 0.05% leukocytes, as determined with a Coulter
counter.
Isolation of Platelet Granules and Preparation of Platelet Granule
Sonicate—Platelet concentrate was kept on ice and was cavitated three
times for 15 min under nitrogen at 60 atmosphere in a cavitation
chamber (Parr Instrument Co, Moline, IL). Cavitate was collected in
siliconized polypropylene tubes (Becton-Dickinson, Leiden, The Neth-
erlands). Cavitation resulted in 90% homogenization of the platelets as
determined with a Coulter counter. Intact and disrupted platelets were
removed by centrifugation (5,000 3 g, 20 min). The supernatant was
collected and centrifuged at 12,000 3 g for 20 min to pellet the granules.
The pellet was resuspended in 5% acetic acid and sonicated for 30 s on
ice to disrupt the granules, using a Branson model B15 sonifier (Bran-
son, Soest, The Netherlands). The granule sonicate was kept at 4 °C for
24 h to extract protein and was subsequently centrifuged at 125,000 3
g for 60 min to remove granule debris. The supernatant containing the
extracted proteins was dialyzed against 5% acetic acid using 3,500-kDa
molecular mass cut-off dialysis tubing (Spectrum, Breda, The Nether-
lands). Protein concentration was determined using a BCA protein
assay kit (Pierce).
Purification of Thrombocidins from Platelet Granule Sonicate—To
purify the major antibacterial proteins from human platelet granule
sonicate to homogeneity, a rapid two-step protocol was applied. As the
first step we used a CM-Sepharose (Amersham Pharmacia Biotech) ion
exchange column (2.5 3 30 cm) equilibrated in phosphate buffer (50
mM, pH 7.0). 25 ml of sonicate obtained from approximately 40 buffy
coats and containing 3.5 mg protein/ml was applied to the column at 0.8
ml/min. The column was washed with phosphate buffer at 0.8 ml/min,
and protein was eluted in a linear salt gradient from 0 to 1 M NaCl in
phosphate buffer. Fractions of 4 ml were collected and dialyzed against
1% acetic acid. Cationic antibacterial proteins were detected using acid
urea polyacrylamide gel electrophoresis (AU-PAGE) and gel overlay
assays (see below). Fractions containing antibacterial proteins were
pooled and lyophilized. Proteins were further purified using CAU-
PAGE as described by Harwig et al. (44) with slight modifications. A
cylindrical gel (3.7 cm in diameter, 7 cm high; 12.5% acrylamide, 5%
acetic acid, 5 M urea) was prepared in a model 491 Prep Cell (Bio-Rad).
The gel was polymerized at 37 °C and prerun at 200 V for 2 h in 5%
acetic acid. Protein was dissolved in sample buffer (3 M urea in 5% acetic
acid with methyl green as the tracking dye) and electrophorized at 40
mA with reversed polarity. Protein was eluted in 5% acetic acid at 0.8
ml/min and collected in fractions of 4 ml. Antibacterial proteins were
detected by AU-PAGE and gel overlay assays (see below).
Purification of NAP-2, CTAP-III, and PF-4—Because TC-1 and TC-2
appeared to be variants of the CXC chemokines NAP-2 and CTAP-III,
we tested the antibacterial activity of these proteins, as well as of PF-4,
another platelet CXC chemokine. CTAP-III, NAP-2, and PF-4 were
purified from release supernatants of thrombin-stimulated platelets, as
described previously (45–48). Briefly, CTAP-III (together with other
variants of b-thromboglobulin antigen) was absorbed by immunoaffin-
ity chromatography and then purified to homogeneity using sequential
cation exchange (45) and reversed-phase chromatography (46). NAP-2
was then generated from CTAP-III by limited digestion with chymo-
trypsin and purified by reversed-phase chromatography (47). PF-4 was
isolated from the flow-through of the immunocolumn obtained after
absorption of b-thromboglobulin antigen and then further purified by
sequential heparin-Sepharose and reversed-phase chromatography
(48). All chemokine preparations exceeded 99% purity and contained no
detectable protein contaminants as judged from analysis by silver-
stained SDS-PAGE and by automated N-terminal sequence analysis.
The C terminus of CTAP-III and NAP-2 was intact, as probed in
Western blots by reactivity of the chemokines with an antiserum that
required the ultimate amino acid residue for binding to b-thrombo-
globulin proteins (49). Furthermore, the full length of CTAP-III (85
amino acids), NAP-2 (70 amino acids), and PF-4 (70 amino acids) was
verified by matrix-assisted desorption/ionization (MALDI) mass
spectroscopy.
Protein Sequencing and Mass Spectrometry—Sequencing of throm-
bocidins was performed at the Sequencing Unit of the University of
Utrecht by automated Edman degradation (Applied Biosystems model
476A Protein Sequencer, San Jose, CA). Electrospray ionization mass
spectrometry was performed on a hybrid quadrupole time-of-flight mass
spectrometer (Micromass, Manchester, UK), equipped with an on-line
nanoelectrospray interface (capillary tip, 20-mm internal diameter 3
90-mm outer diameter) with an approximate flow rate of 250 nl/min.
This flow was obtained by splitting of the 0.4 ml/min flow of a conven-
tional high pressure gradient system 1 to 1000, using an Acurate flow
splitter (LC Packings, Amsterdam, The Netherlands). Lyophilized sam-
ples were dissolved in water/methanol/acetic acid (50:50:1, v/v/v). Injec-
tions were done with a dedicated micro/nano high performance liquid
chromatography autosampler, the FAMOS (LC Packings, Amsterdam,
The Netherlands) in flow injection analysis mode. Thrombocidins were
treated with trypsin (Difco, Detroit, MI; 1:100, w/w) in ammonium
hydrogen carbonate (50 mM, pH 8.0) for 18 h. Mass spectra of the tryptic
digests were recorded from mass 50–2,000 Da every second with a
resolution of 5000 full width half-maximum. The resolution allows
direct determination of the monoisotopic mass, also from multiple
charged ions. In MS/MS mode, ions were selected with a window of 2 Da
with the first quadrupole, and fragments were collected with high
efficiency with the orthogonal time-of-flight mass spectrometer. The
collision gas applied was argon (4 3 1025 mbar), and the collision
voltage was approximately 30 V.
AU-PAGE—CM-Sepharose and CAU-PAGE-purified proteins were
analyzed using AU-PA slab gels (12.5% acrylamide, 5% acetic acid, 5 M
urea). After polymerization at 37 °C the gels were prerun in 5% acetic
acid at 150 V until the current was constant (;8 mA). Samples to be
analyzed were lyophilyzed, dissolved in 8 ml of sample buffer (3 M urea
in 5% acetic acid with methyl green as the tracking dye) and electro-
phorized in 5% acetic acid at 150 V with reversed polarity. Gels were
either stained with 0.1% Coomassie Blue in 50% methanol and 10%
acetic acid or by silver staining according to Blum et al. (50). Gels run
in parallel were used in overlay assays to localize antibacterial proteins
(see below).
Detection of Antibacterial Proteins by Gel Overlay Assay—Gel overlay
assays to detect activity of antibacterial proteins in acid urea gels were
performed according to Lehrer et al. (51) with minor modifications. The
test strain Escherichia coli ML35 was grown in tryptic soy broth (TSB;
Difco) at 37 °C overnight. This culture was diluted 50 times in fresh
TSB, and bacteria were grown to log phase in 2.5 h. Bacteria were
pelleted at 14,000 3 g for 30 s and washed twice with phosphate-
buffered saline (pH 7.4). For each assay an inoculum of 5 3 107 colony-
forming units was suspended in 15 ml of nutrient-poor agarose of 42 °C
(10 mM sodium phosphate buffer, pH 7.4, 0.06% (w/v) TSB, 1% (w/v)
type I agarose; Sigma). This suspension was poured into a square 12 3
12-cm dish (Hospidex, Nieuwkoop, The Netherlands). Immediately af-
ter electrophoresis, acid urea slab gels were washed three times for 12
min in phosphate buffer (10 mM, pH 7.4) and placed on top of the
bacterial agarose bottom. After incubation at 37 °C for 3 h, the gels were
removed and a nutrient-rich agar (6% (w/v) TSB, 1% (w/v) agar noble;
Difco) was poured over the bottom layer to allow growth of surviving
bacteria. Clear zones after overnight incubation at 37 °C indicated the
presence of antibacterial proteins.
Microbicidal Assay—Microbicidal activity of purified thrombocidins
and of NAP-2, CTAP-III, and PF-4 was quantified in a liquid microbi-
cidal assay. Suspensions of logarithmically growing test bacteria (Ba-
cillus subtilis ATCC6633, E. coli ML35, or S. aureus 42D) were pre-
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pared as described for the overlay assay. Two fungi, Candida glabrata
and Cryptococcus neoformans (both clinical isolates) were maintained
on Isosensitest agar plates (Oxoid, Unipath, Basingstoke, Hampshire,
UK) and cultured for 48 h at 30 °C in 0.7% (w/v) yeast nitrogen base
(YNB; Difco), supplemented with 0.15% (w/v) L-asparagine (Merck) and
1% (w/v) glucose (Merck). Bacteria and fungi were diluted to 1–2 3 105
colony-forming units/ml in 10 mM phosphate buffer (pH 7.0) 1 0.06%
(w/v) TSB. 2-fold serial dilutions of the protein to be tested were pre-
pared in 0.01% acetic acid, and 5-ml aliquots were transferred to a low
protein binding polypropylene microtiter plate (Costar, Cambridge). To
each of the wells, 45 ml of the bacterial suspension was added. The plate
was incubated on a rotary shaker (300 rpm) at 37 °C. After 2 h, aliquots
of 0.5 and 10 ml were plated on blood agar plates (bacteria) or isosen-
sitest agar plates (fungi) and incubated at 37 °C. Alternatively, 10-ml
aliquots were spotted in duplicate on plates that had been dried for 1 h
at 37 °C. In some cases, 150 ml of TSB was added to the remainder of the
incubations, and the microtiter plate was incubated at 37 °C. Microbi-
cidal activity was assessed the next day (bacteria) or after 48 h (fungi)
after counting colonies on the agar plates and by visual inspection of
growth in the microtiter plates. MBC and MFC were defined as the
concentration of protein at which ,0.1% of the inoculum survived
after the 2 h of exposure. All experiments were performed at least in
duplicate.
Measurements of Membrane Potential (Dc) of Lactococcus lactis—The
influence of TCs on membrane potential was assessed using L. lactis IL
1403 (52). This strain was grown at 30 °C in M17 broth (Oxoid) supple-
mented with 25 mM galactose plus 50 mM L-malate. The cells were
harvested in the mid-exponential phase of growth and washed and
resuspended in 50 mM potassium phosphate (pH 6.5 or 5.0). The mem-
brane potential (Dc) was measured using the Dc-sensitive fluorescent
dye 3,39-dipropylthiadicarbocyanine iodide (diS-C3(5)). The cells were
diluted to a final concentration of 20 mg of protein/ml in 50 mM KPi of
the indicated pH and equilibrated at 30 °C; the final diS-C3(5) concen-
tration was 3 mM. The excitation and emission wavelengths were 643
and 666 nm, respectively. The membrane potential was generated upon
addition of either 25 mM of glucose or 25 mM of L-malate as source of
metabolic energy.
RESULTS
Purification of Thrombocidins from Platelet Granule Soni-
cate—We used CM-Sepharose cation exchange chromatogra-
phy followed by CAU-PAGE to purify the major antibacterial
proteins from granule sonicate to homogeneity. Fractions ob-
tained after CM-Sepharose chromatography were analyzed on
two acid urea gels run in parallel. One gel was silver-stained
(Fig. 1A), and the other was used to assay antibacterial activity
in an overlay assay (Fig. 1B). The antibacterial activity present
in the crude granule sonicate (Fig. 1, son lanes) was separated
from the bulk of the protein (fraction 10) and eluted in fractions
35–75 in the salt gradient. The major antibacterial activity
could be assigned to two proteins present in fractions 45–75
(Fig. 1B). These fractions were pooled, dialyzed extensively
against 0.1% HAc, lyophilized, and subjected to CAU-PAGE.
Fractions were again analyzed on two acid urea gels run in
parallel, one of which was silver-stained (Fig. 1C) while the
other was analyzed for antibacterial activity in an overlay
assay (Fig. 1D). Both crude granule sonicate and the CM-
Sepharose-purified thrombocidins were included in this analy-
sis. The CM-Sepharose-purified preparation appeared to con-
tain two antibacterial proteins. The most cationic protein was
designated as TC-1, and the second, slightly less cationic one
was designated as TC-2. After CAU-PAGE these proteins were
FIG. 1. Purification of thrombocidins by CM-Sepharose chromatography and CAU-PAGE. Thrombocidins were prepurified from
platelet granule sonicate by CM-Sepharose chromatography (A and B). Of the indicated fractions, 50-ml aliquots were analyzed on two acid urea
gels run in parallel, followed by silver staining of one gel (A) and an overlay assay of the other gel (B). Fractions containing antibacterial protein
were pooled and further purified by CAU-PAGE (C and D). Fractions collected in the second purification step were also analyzed on acid urea gels,
followed by silver staining (C) and overlay assay (D). Platelet granule sonicate (son) and CM-Sepharose-purified thrombocidins (CM) were included.
E. coli ML35 was used as the test organism in the overlay assays (B and D).
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effectively separated, with TC-1 collected in fractions 35–41
and TC-2 in 45–51 (Fig. 1C). In the AU gels, TC-1 and TC-2
migrate at positions identical to the main antibacterial activi-
ties in crude platelet sonicate (Fig. 1, C and D). TC-1 and TC-2
thus can be considered to be major antibacterial compounds in
platelet granules. Processing of 1013 platelets (from 10 liters of
blood) yielded approximately 750 mg of pure TC-1 and TC-2.
Characterization of TC-1—Several attempts to determine
the N-terminal sequence of TC-1 by Edman degradation were
not successful. Mass spectrometrical techniques were used to
elucidate the structure of TC-1. Analysis by MALDI spectrom-
etry revealed that the purified TC-1 preparation contained a
7,435.9-Da protein, together with minor amounts of proteins of
similar size (Table I). Electrospray spectrometry revealed a
mass of 7,436.3 Da, confirming the mass of the major protein in
the preparation, identified by MALDI. This component will
further be referred to as TC-1. Sequence data were obtained by
trypsin digestion of TC-1 followed by mass spectrometrical
analyses in MS/MS mode of the resulting fragments. The se-
quences of two fragments, of 839.5 and 590.3 Da, were TTSGI-
HPK and LAGDES, respectively. These sequences were iden-
tical to internal sequences of platelet basic protein (PBP), a
10,262-Da platelet protein (Table I and Fig. 2). The mass of
undigested TC-1 was less than that of PBP and even smaller
than the smallest known degradation product of PBP, NAP-2
(7,623 Da). The difference of 186 Da can be explained by as-
suming that TC-1 is NAP-2, truncated C-terminally by two
amino acids (Ala-Asp). The presence of a 590.3-Da C-terminal
fragment, LAGDES, and the absence of a fragment with the
mass of LAGDESAD in the tryptic digest of TC-1 confirm the
C-terminal truncation.
In the MALDI spectrum of TC-1, three minor proteins were
observed (TC-1a, TC-1b, and TC-1c; Table I). The sequences of
these proteins have not been determined directly, but their
recorded masses can be explained by assuming that they also
are derivatives of PBP, having N and C termini slightly differ-
ent from TC-1. The N terminus of TC-1 and of NAP-2 results
from cleavage of PBP between Tyr24 and Ala25, the cleavage
site of chymotrypsin (45, 53). TC-1a has an molecular mass of
7,600.6 Da, 164 Da larger than TC-1. This suggests the pres-
ence of an N-terminal tyrosine preceding Ala25, possibly result-
ing from alternative cleavage between Leu23 and Tyr24 in PBP.
Two other minor compounds were TC-1b and TC-1c with mo-
lecular masses of 7219.3 and 7106.2 Da, respectively. These
values correspond to masses of proteins derived from TC-1 by
further truncation by two (ES) or three (DES) C-terminal
amino acids (Table I).
Characterization of TC-2—The N-terminal sequence of TC-2
was determined by Edman degradation to be NLAKG-
KEESLDSDLY, which is identical to the N-terminal sequence
of CTAP-III. CTAP-III is a major platelet a-granule protein
and, like NAP-2, a known degradation product of PBP (Fig. 2).
The molecular mass of TC-2 was 9100.5 Da as determined by
electrospray mass spectrometry (Table I). This is less than the
theoretical molecular mass of CTAP-III (9287.7 Da), which can
be explained by the absence of the two C-terminal amino acids
(Ala-Asp) present in CTAP-III. The calculated mass of this
molecule (9101.5 Da) is in accordance with the mass found
experimentally for TC-2. Analysis of tryptic fragments of TC-2
revealed the presence of a 590.3-Da fragment with the se-
quence LAGDES, confirming the C-terminal truncation as in
TC-1 (Table I). Of TC-2, two other fragments were identified,
TTSGIHPK (839.5 Da) and GKEESLDSDL (1091.5 Da), the
latter of which is absent in TC-1, as expected (Table I and Fig.
2). In the MALDI spectrum of TC-2 one minor peak was de-
tected (TC-2a; Table I) with a molecular mass of 10,081 Da.
This value corresponds to the mass of PBP, truncated C-termi-
nally by two amino acids (Ala-Asp). This molecule could be a
precursor of TC-2.
Bactericidal Activity of Thrombocidins—Bactericidal activity
of purified TC-1 and TC-2 was investigated by determination of
their MBC values for S. aureus 42D, B. subtilis ATCC6633, and
E. coli ML35 (Fig. 3). B. subtilis was the most susceptible
organism with MBCs of 0.4 and 0.7 mM for TC-1 and TC-2,
respectively. E. coli ML35 was somewhat less susceptible, with
MBC values of 3.4 and 2.7 mM for TC-1 and TC-2, respectively.
MBCs for TC-1 and TC-2 for S. aureus 42D were 6.8 and 11 mM,
respectively (Fig. 3). Incubations from which no bacteria could
be recovered after 2 h of incubation never showed visible
growth after addition of growth medium and overnight incuba-
tion (not shown).
Kinetics of bactericidal activity was investigated by exposure
TABLE I
Characterization of thrombocidins
Molecular masses of TC-1 and TC-2 were determined by electrospray and MALDI-time of flight mass spectrometry. Trypsin-treated TCs were
analyzed by electrospray mass spectrometry, and sequences of selected fragments were determined in MS/MS mode. Theoretical molecular masses
of TCs are based on average masses, and those of tryptic fragments are based on mono-isotopic masses.
Component Experimentalmolecular masses







Electrospray 7436.3 Ala25–Ser92 7437.5
Proteins in MALDI spectrum
TC-1 7435.9 Ala25–Ser92 7437.5
TC-1ab 7600.6 Tyr24–Ser92 7600.7
TC-1bb 7219.3 Ala25–Asp90 7220.9
TC-1cb 7106.2 Ala25–Gly89 7105.8
Tryptic fragments 839.5 Thr34–Lys41 839.5
590.3 Leu87–Ser92 590.3
Thrombocidin-2
Electrospray 9100.5 Asn10–Ser92 9101.5
Proteins in MALDI spectrum
TC-2 9106 Asn10–Ser92 9101.5
TC-2ab 10081 Ser1–Ser97 10075.6
Tryptic fragments 839.5 Thr34–Lys41 839.5
590.3 Leu87–Ser92 590.3
1091.5 Gly14–Leu23 1091.5
a Amino acid numbering of PBP as in Fig. 3.
b Minor component.
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of B. subtilis to 3 mM of TC (Fig. 4). Killing by TC-1 appeared to
be very rapid, causing a 3-log fold reduction of the inoculum
within 1 min, and a 5-log fold reduction within 5 min. At 3 mM,
killing by TC-2 was slower, reaching 3-log and 5-log fold reduc-
tion after 25 and 30 min, respectively (Fig. 4).
Fungicidal Activity of Thrombocidins—Fungicidal activity of
thrombocidins was tested using the same experimental set up
as for the bactericidal activity testing. Both TC-1 and TC-2
appeared to be inactive against C. glabrata up to 30 mM (Table
II). C. neoformans, however, was highly susceptible to TC-1
with an MFC of 1.9 mM (Table II). TC-2 was less active (MFC of
30 mM) but still capable of killing this organism.
Antibacterial Activity of NAP-2, CTAP-III, and PF-4—To
investigate whether antibacterial activity is a general charac-
teristic of platelet CXC chemokines, purified NAP-2, CTAP-III,
and PF-4 were tested in a bactericidal assay. Each chemokine
was tested up to a concentration of 30 mM against B. subtilis,
E. coli, S. aureus, and C. neoformans. None of the proteins was
bactericidal for these organisms, although PF-4 had some ac-
tivity against B. subtilis, reducing the viable count by approx-
imately 90% at 30 mM (not shown).
Membrane Activity of TCs—L. lactis IL1403 was highly sus-
ceptible to TC-1 and had an MBC of 0.5 mM. Because many
antimicrobial peptides have been shown to act via Dc-dissipat-
ing processes (54–56), the Dc-sensitive fluorescent dye diS-
C3(5) was used to assess the effects of TC-1 and TC-2 on the
membrane potential generated by glycolyzing or L-malate-me-
tabolizing cells of L. lactis IL1403. The degree of fluorescence
quenching of diS-C3(5) is directly proportional to the mem-
brane potential across the cytoplasmic membrane of the cells.
In glycolyzing cells of L. lactis, the membrane potential is
generated by proton extrusion via the F0F1-ATPase after sugar
breakdown in the Embden-Meyerhof pathway, whereas in L-
malate-metabolizing cells the membrane potential results from
the electrogenic exchange of L-malate for L-lactate (57). The
latter pathway, which is malolactic fermentation, only involves
one enzyme, i.e. malolactic enzyme, in addition to the L-malate/
L-lactate exchanger. If the TC-induced killing results from the
dissipation of the ion gradients across the membrane, e.g. as a
result of pore formation, a lowering of the membrane potential
should be observed both in glycolyzing and L-malate-metabo-
lizing bacteria. These pathways generate the membrane poten-
FIG. 2. Sequence alignment of thrombocidins and related chemokines.
FIG. 3. Bactericidal activity of
thrombocidins. Bacteria in logarithmic
phase (E. coli ML35, B. subtilis
ATCC6633, or S. aureus 42D; 1–2 3 105
colony-forming units/ml) were exposed to
TC-1 and TC-2 serially diluted in 10 mM
phosphate buffer (pH 7.0) 1 0.06% (w/v)
TSB for 2 h at 37 °C. Colonies were
counted after plating incubations on blood
agar plates. Experiments were performed
at least in duplicate; results from dupli-
cate incubations never differed .20%.
MBCs never differed more than one dilu-
tion step.
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tial via completely different mechanisms with no common steps
involved (58). A decrease in the membrane potential in both
systems would thus provide a very strong argument for pore
formation in the membrane (52).
Fig. 5A shows that TC-1 and TC-2, at a final concentration of
2 mM, do not affect the membrane potential in glycolyzing cells
of L. lactis IL1403. As a control, the depolarization of the
membrane potential by the lantibiotic nisin is shown. Simi-
larly, in cells metabolizing L-malate at high rate, the addition of
TC-1 (Fig. 5B) or TC-2 (not shown) had no effect.
Because the net effect on the membrane potential will be the
resultant of putative pore formation and the capacity to gener-
ate a membrane potential, we also determined the effect of
TC-1 and TC-2 under conditions that membrane potential gen-
eration is limited. For this, L. lactis IL1403 cells metabolizing
L-malate were incubated at pH 5.0 in the presence of the
ionophore nigericin. Nigericin dissipates the pH gradient
across the membrane, and under these conditions the mem-
brane potential is the only component of the proton motive
force. Importantly, the internal pH is now similar to the exter-
nal one, which is 5.0, and malolactic fermentation is highly
compromised. This results in limited capacity to generate a
membrane potential. Under these conditions a small depolar-
izing effect of TC-1 and TC-2 on the membrane potential was
observed (Fig. 5C). The nature of this depolarizing effect is
unknown but is unlikely to be relevant with respect to the
observed cidal effect. The depolarization of the membrane po-
tential by the lantibiotic nisin is again shown as a control; the
further addition of the potassium ionophore valinomycin indi-
cates that nisin nearly completely dissipated the membrane
potential at the concentration tested.
These data are in agreement with initial experiments using
liposomes prepared from E. coli phospholipids in 50 mM potas-
sium phosphate. A diffusion membrane potential was gener-
ated by incubating these liposomes in 50 mM sodium phosphate
and was monitored by the addition of diS-C3(5). TC-1 or TC-2
did not dissipate the membrane potential because quenching of
diS-C3(5) could not be relieved by either protein (not shown).
In summary, under conditions similar to those that kill L.
lactis IL1403, no significant effect of TC-1 or TC-2 was ob-
served on its membrane potential nor on the membrane poten-
tial of E. coli liposomes. We thus conclude that there is no direct
evidence for pore formation in the L. lactis cytoplasmic mem-
brane or the liposomes by either TC-1 or TC-2 and that it is
FIG. 4. Kinetics of bactericidal activity of TC-1 and TC-2
against B. subtilis ATCC6633. Bacteria (1 3 105 colony-forming
units/ml) grown to log phase were exposed to 3 mM TC-1 (E) or TC-2 ( l )
at 37 °C. At given timepoints, aliquots were plated on blood agar plates,
and colonies were counted the next day. The average of three independ-
ent experiments (6 S.D.) are given.
TABLE II
Fungicidal activity of thrombocidins
Fungi (1–2 3 105 cfu/ml) were exposed to TC-1 and TC-2 serially
diluted in 10 mM phosphate buffer (pH 7.0) 1 0.06% (w/v) TSB for 2 h
at 37 °C. Minimal fungicidal concentrations were determined after plat-






C. neoformans 1.9 30
C. glabrata .30 .30
FIG. 5. Effect of thrombocidins on the Dc of glycolyzing and
malate-metabolizing L. lactis IL 1403 cells. A, L. lactis cells were
resuspended to a final protein concentration of 20 mg of protein/ml in 50
mM potassium phosphate (pH 6.5) containing 3 mM diSC3(5). At time 0
(not depicted), glucose was added to a final concentration of 25 mM,
which resulted in the generation of a membrane potential (observed as
a decrease in fluorescence). After about 4 min, TC-1 (2 mM), TC-2 (2 mM),
or nisin (1 mM) was added. Further details are described under “Exper-
imental Procedures.” B, experimental conditions were the same as
those described for A, except that the pH was 5.0, and 25 mM L-malate
was used to energize the cells. After about 2 min, TC-1 (1 mM) or nisin
(0.5 mM) was added. C, experimental conditions were the same as
described for B, except that nigericin was present at 0.5 mM. The
additions of TC-1 (1 mM), TC-2 (1 mM), solvent control, nisin (0.5 mM), and
valinomycin (0.5 mM) are indicated.
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unlikely that such a mechanism is the primary cause for the
cidal activity of these compounds.
DISCUSSION
Although the presence of antibacterial proteins in human
and rabbit platelets has been recognized for over 30 years (31,
32), their identity has never been elucidated. We now show that
the two major bactericidal proteins, TC-1 and TC-2 (thrombo-
cidins, for thrombocyte microbicidal proteins), are truncated
forms of NAP-2 and CTAP-III, respectively, differing from
these CXC chemokines by the absence of the 2 C-terminal
amino acids. TC-1 and TC-2 were bactericidal for the Gram-
positive B. subtilis and S. aureus as well as for the Gram-
negative E. coli test strain, with MBCs ranging from 0.4 mM
(TC-1, B. subtilis) to 11 mM (TC-2, S. aureus).
TC-1 was highly and TC-2 was moderately active against the
fungus C. neoformans, whereas neither TC was active against
Candida species. Preparations from rabbit platelets containing
PMPs were more active against Candida species than against
C. neoformans (59), indicating that the antimicrobial spectra of
the human TCs and rabbit PMPs are different.
The MBC of TC-2 for E. coli was 2.7 mM, but at 5.5 and 11 mM
some bacteria were reproducibly recovered (Fig. 3), indicating
an optimum concentration for activity. A similar phenomenon
has been observed for the killing of certain staphylococcal and
streptococcal strains by b-lactam antibiotics and was termed
the “paradoxical” response (60) or tolerance (61). Whether tol-
erance for TC-2 or other cationic antibacterial peptides exists
in E. coli requires further investigation.
TC-1 only differs from NAP-2 and TC-2 only differs from
CTAP-III by the absence of two C-terminal amino acids. This
truncation is essential for bactericidal activity, because puri-
fied NAP-2 and CTAP-III at concentrations up to 30 mM did not
kill B. subtilis, E. coli, and S. aureus. This difference in activity
may indicate that the C-terminal part of TCs is involved in the
cidal mechanism. The C termini of all CXC chemokines extend
as an a-helix (62, 63). Antibacterial a-helical proteins like the
cecropins are thought to insert into the membrane, thereby
killing the bacteria (6). If thrombocidins also interact with
membranes by their a-helical domain, the structural require-
ments for the C-terminal helix apparently are very strict. The
two C-terminal amino acids present in NAP-2 and CTAP-III
may block antibacterial activity possibly by influencing charge
distribution (64), because the C-terminal residue in NAP-2 and
CTAP-III is the acidic aspartic acid.
At present, it is unclear how PBP is processed to finally yield
TCs. The N terminus of TC-1 and NAP-2 are identical. NAP-2
is thought to be formed extracellularly from released PBP and
CTAP-III, by neutrophil (65) or monocyte proteases (66) like
cathepsin G (45, 66, 67). Because we have isolated TC-1 di-
rectly from platelet granules, at least some cathepsin G-like
protease activity must be present inside the platelets. Because
TC-1 and TC-2 are C-terminally truncated NAP-2 and CTAP-
III, respectively, the platelets (platelet granules) must also
contain carboxypeptidase activity. Interestingly, we have iden-
tified a protein with the molecular mass of PBP with a C-
terminal truncation of two residues (TC-2a; Table I) that may
be a precursor for TC-1 and TC-2.
TC-1 and TC-2 killed the entire B. subtilis inoculum within 5
and 30 min, respectively (Fig. 4). These fast kinetics are char-
acteristic for various bactericidal proteins and are often asso-
ciated with membrane disturbance (6). Dissipation of mem-
brane potential by the formation of voltage-dependent channels
has therefore been implicated as a general mechanism of pep-
tide antibiotic-mediated killing activity (6). Under the experi-
mental conditions used, however, TCs did not dissipate the Dc
of whole L. lactis bacteria nor of liposomes composed of E. coli
lipids. Apparently, their target for microbial killing is located
elsewhere, most likely intracellularly. Under conditions when
L. lactis had limited capacity to generate a membrane poten-
tial, a small decline in Dc was observed in the presence of TC-1
(Fig. 5C). This suggests that even though no dissipation of the
membrane potential occurs, TCs do interact with the mem-
brane. Whether TCs can passively cross the membrane and
reach putative intracellular targets remains to be established.
Rabbit PMPs dissipated the Dc of S. aureus cells (56, 68).
The structures of these peptides have not been reported, but
their amino acid composition (69) differs from those of TCs.
Although test conditions were not identical, our studies indi-
cate that human and rabbit microbicidal proteins not only
differ structurally but also differ in their mode of action.
In this study we used sonicated granules of human platelets
as the source for TC purification. An important question is
whether the amount of TC in platelets would be sufficient for in
vivo microbicidal activity. We could purify relatively low
amounts of TC, but it is unclear whether the procedure is
quantitative and thus how much is contained within platelets.
Furthermore, the amount of TC released in vivo depends on
strength of platelet activation, whereas local concentration of
TC is influenced by blood flow and adhesion of TC to cellular
components and blood proteins. A process possibly adding to
the local concentration of TCs is the extracellular generation of
these proteins by C-terminal truncation of platelet-secreted
PBP, CTAP-III, and NAP-2 by proteases present in the (inflam-
matory) environment. From the issues discussed above, it may
be expected that TCs act highly locally, possibly even requiring
close contact of platelets with their targets. The fact that mi-
croorganisms can aggregate and activate platelets (35, 70) may
facilitate the microbicidal effect. Evidence for a role of TCs as
effective antiinfectives in vivo was obtained in a separate
study,2 where rabbits were vaccinated with human platelet
sonicate to induce antibodies neutralizing the rabbit platelet
microbicidal activity. These rabbits had an increased suscepti-
bility to experimental IE. The sera of vaccinated rabbits, but
not the control sera, neutralized microbicidal activity of plate-
let releasates in vitro and contained antibodies recognizing TCs
in Western blots. These observations support the hypothesis
that the enhanced susceptibility to IE of the vaccinated rabbits
was due to the neutralization of the rabbit platelet microbicidal
proteins.2
The thrombocidins are two novel CXC chemokine molecules
with a function previously unknown to the large family of
chemokines. Thus, platelet chemokines, liberated to enhance
defense reactions by attracting and activating neutrophils and
initiating wound healing by activating fibroblasts, may also be
a rich local source for the generation of potent antimicrobials,
underscoring the importance of platelets in innate host
defense.
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